Guillem Laporta, CFA

Guillem Laporta is a Partner at Ysios Capital, where he plays a crucial role in identifying and evaluating investment opportunities. He has amassed over 10 years of experience in the venture capital sector, particularly focusing on biotechnology investments.

Professional Background

Before joining Ysios Capital, Guillem worked at the Edmond de Rothschild Group in Paris (now known as Andera Partners), where he contributed to several significant investments in both Europe and the United States. His notable projects include involvement with companies such as Reviral, which was sold to Pfizer, Axonics Modulation (currently valued at $3 billion on Nasdaq), and Sanifit, sold to Vifor. Earlier in his career, he served as an analyst at Caixa Capital Risc, specifically within the life sciences team.124

Education and Credentials

Guillem holds dual Bachelor's degrees: one in Biotechnology from the Universitat Autonoma de Barcelona and another in Business Administration from the Universitat Pompeu Fabra. He is also a CFA charterholder, indicating his expertise in financial analysis and investment management.13

Current Roles

In addition to his responsibilities at Ysios Capital, Guillem serves on the board of VarmX and acts as a board observer for Engrail Therapeutics, further showcasing his involvement in the biotechnology sector.12

Guillem Laporta's combination of scientific knowledge and financial acumen positions him as a key player in venture capital investments within the life sciences field.